EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Championing Hypertension Remote Monitoring for Equity and Dissemination (CHARMED): A multi-site factorial randomized controlled trial protocol

Courtney R Lyles, Elaine C Khoong, Rachel J Stern, Nooshin Abtahi, Anjana E Sharma, Mark J Pletcher, Fan Xia, Faviola Garcia, Nilpa D Shah, Lina Tieu, Urmimala Sarkar, CHARMED consortium

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2025.107879 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Courtney R Lyles und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Healthcare Research and Policy, University of California Davis, Davis, CA, USA; Division of General Internal Medicine, Department of Medic…. Hauptthemen laut MEDLINE: Hypertension, Blood Pressure Monitoring, Ambulatory. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, California Health Care Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: We have evidence-based strategies such as remote patient monitoring and digital health tools to improve hypertension outcomes. Still, we lack large-scale studies focusing on disseminating these practices into routine clinical care. This is especially important to study within safety-net healthcare settings that disproportionately care for marginalized patient populations. METHODS: We will conduct a hybrid type 1 implementation trial (2 × 2 factorial design) with 25 safety-net clinics across three of California's public healthcare delivery systems, enrolling 2500 English- and Spanish-speaking patients with uncontrolled hypertension. Clinics will be randomized to receive baseline training on best practices in remote monitoring for hypertension management vs. training plus ongoing practice facilitation to support its implementation. Patients within these clinics will be randomized to receive cellular-enabled blood pressure monitors and automatic text message reminders to check their blood pressure at home vs. receipt of the same monitors as well as additional support via individually tailored text message feedback and support for hypertension management. RESULTS: The primary outcome will be a change in systolic blood pressure collected during routine office visits. Secondary outcomes include changes in home blood pressure and patient-reported assessments of clinical care and medication adherence. Given the hybrid type I trial implementation, the primary implementation outcomes will be the adoption of intervention at the patient and clinic levels. DISCUSSION: The evidence from this trial will advance implementation-focused research on hypertension management, such as the essential combination of both patient- and clinic-facing intervention strategies. TRIAL REGISTRATION: NCT, NCT06113458. Registered 23 October 2023, https://clinicaltrials.gov/study/NCT06113458.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionBlood Pressure Monitoring, AmbulatoryHumansRandomized Controlled Trials as TopicMulticenter Studies as TopicTelemedicineText MessagingCaliforniaSafety-net ProvidersAntihypertensive AgentsReminder SystemsBlood Pressure

Stichwörter der Autor:innen

Digital healthHome blood pressure monitoringHypertensionRemote patient monitoring

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Center for Healthcare Research and Policy, University of California Davis, Davis, CA, USA; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; D…
  • Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; UCSF Action Research Center for Health Equity, Zuckerberg San Francisco General Hospital, Un…
  • Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Ventura County Health Care Agency, Ventura, CA, USA.
  • Contra Costa Health Services, CA, USA.
  • UCSF Action Research Center for Health Equity, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA; Department of Family and Community Medicine, University of Califo…
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • California Health Care Foundation
  • Gordon and Betty Moore Foundation
  • Patient-Centered Outcomes Research Institute
  • Agency for Healthcare Research and Quality
  • U.S. Food and Drug Administration
  • Doctors Company Foundation

Zitieren

APA

Lyles, C. R., Khoong, E. C., Stern, R. J., Abtahi, N., Sharma, A. E., Pletcher, M. J., Xia, F., Garcia, F., Shah, N. D., Tieu, L., Sarkar, U., & CHARMED consortium (2025). Championing Hypertension Remote Monitoring for Equity and Dissemination (CHARMED): A multi-site factorial randomized controlled trial protocol. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107879

Vancouver

Lyles CR, Khoong EC, Stern RJ, Abtahi N, Sharma AE, Pletcher MJ, et al. Championing Hypertension Remote Monitoring for Equity and Dissemination (CHARMED): A multi-site factorial randomized controlled trial protocol. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107879

BibTeX
@article{Lyles2025,
  author = {Lyles, Courtney R and Khoong, Elaine C and Stern, Rachel J and Abtahi, Nooshin and Sharma, Anjana E and Pletcher, Mark J and Xia, Fan and Garcia, Faviola and Shah, Nilpa D and Tieu, Lina and Sarkar, Urmimala and CHARMED consortium, CHARMED consortium},
  title = {Championing Hypertension Remote Monitoring for Equity and Dissemination (CHARMED): A multi-site factorial randomized controlled trial protocol},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2025.107879}
}
Kostenlos starten →